Establishment of mRNA-LNP Vaccine Stability Analysis Platform
Securing the Foundation for Quality Control of Next-Generation Vaccines

GC Green Cross announced on August 7, 2026, that research results providing a precise analysis of the physicochemical stability and changes of mRNA-LNP vaccines have been published in the SCIE-level international academic journal 'Pharmaceuticals Research.'

Overview of GC Green Cross Headquarters. GC Green Cross

Overview of GC Green Cross Headquarters. GC Green Cross

View original image

The research team conducted rigorous tests simulating distribution and storage conditions—such as temperature, oxidation, hydrolysis, and physical agitation—that vaccines might experience. Through these tests, they analyzed the correlations among mRNA purity, structural changes in lipid nanoparticles (LNP), and the efficacy of protein expression in vitro.


A wide range of analytical techniques was used in the study, including ion-pair reversed-phase liquid chromatography (IP-RP HPLC), capillary electrophoresis (CE), ultra-performance liquid chromatography with charged aerosol detection (UPLC-CAD), cryogenic transmission electron microscopy (Cryo-TEM), and mass spectrometry (LC-MS/MS).


GC Green Cross stated that this research led to the establishment of an integrated analytical platform for verifying the quality and stability of mRNA pharmaceuticals. They plan to use this platform to optimize manufacturing processes and quality control for both the COVID-19 mRNA vaccine currently under development and other mRNA-based vaccines and therapeutics.



Hong Jungwoon, R&D QM Unit Head at GC Green Cross, commented, “We analyzed the relationships between mRNA quality attributes and degradation mechanisms and proposed an integrated analytical strategy for stability assessment,” and added, “It will be utilized as a quality standard for the commercialization of mRNA-based products in the future.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing